Asuragen spins off new miRNA company

Austin-based Asuragen is spinning off its miRNA therapeutic intellectual property into a new company and seeding it with $3 million in cash. Working with Yale University researchers, Mirna will pursue the development of synthetic miRNA to beef up the presence of these small RNAs. Low levels of miRNA are recorded in a variety of cancers, and adding substitute miRNA may prove to be a significant new development field.

"The discovery of miRNAs represents a paradigm changing event in biology and medicine of a magnitude that only occurs once every decade or two," said Matt Winkler CEO/CSO of Asuragen. "They likely will become a major new class of drugs."


- check out the press release

Related Articles:
Asuragen rounds up $49M in first round. Report
Asuragen outlines start-up plans. Report

Suggested Articles

Janssen’s BCMA-targeting CAR-T therapy eliminated tumors in 69% of patients with advanced multiple myeloma in a small phase 1 study.

In a study, BMS' CAR-T therapy banished tumors in more than half and shrank tumors in nearly three-quarters of relapsed blood cancer patients.

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.